Clinical Trial Update: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating lisocabtagene maraleucel as first-line therapy for transplant-ineligible primary central nervous system lymphoma; study status is recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Breyanzi (lisocabtagene maraleucel)

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Lymphoma | Phase 2 | Status: RECRUITING